Virucidal efficacy of guanidine-free inactivants and rapid test buffers against SARS-CoV-2

A pathogen inactivation step during collection or processing of clinical samples has the potential to reduce infectious risks associated with diagnostic procedures. It is essential that these inactivation methods are demonstrated to be effective, particularly for non-traditional inactivation reagent...

Descripción completa

Detalles Bibliográficos
Autores principales: Davies, Katherine, Arnold, Ulrike, Buczkowski, Hubert, Burton, Christopher, Welch, Stephen R., Green, Nicole, Strachan, Rhea, Beetar-King, Tracy, Spencer, Peter, Hettiarachchi, Nipunadi, Hannah, Matthew J., Jones, Matthew, Cane, Patricia A., Bruce, Christine B., Woodford, Neil, Roberts, Allen D. G., Killip, Marian J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642387/
https://www.ncbi.nlm.nih.gov/pubmed/34862448
http://dx.doi.org/10.1038/s41598-021-02942-4
Descripción
Sumario:A pathogen inactivation step during collection or processing of clinical samples has the potential to reduce infectious risks associated with diagnostic procedures. It is essential that these inactivation methods are demonstrated to be effective, particularly for non-traditional inactivation reagents or for commercial products where the chemical composition is undisclosed. This study assessed inactivation effectiveness of twenty-four next-generation (guanidine-free) nucleic acid extraction lysis buffers and twelve rapid antigen test buffers against SARS-CoV-2, the causative agent of COVID-19. These data have significant safety implications for SARS-CoV-2 diagnostic testing and support the design and evidence-based risk assessment of these procedures.

Ejemplares similares